Catalyst Wire Dossier Catalyst Wire Dossier

Pelacarsen (TQJ230)

pelacarsen · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Pelacarsen (TQJ230), covering 2025-02-14 to 2026-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD [Phase 3]

See pricing